Official ESCRS | European Society of Cataract & Refractive Surgeons
Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

Corneal collagen cross-linking efficacy in central and paracentral ectasias

Poster Details

First Author: B. Gargallo Martinez SPAIN

Co Author(s):    E. Rubio Velazquez   A. Ruiz Hernandez   A. Navarro Valverde   R. Gutierrez Ortega           

Abstract Details

Purpose:

To compare the efficacy of corneal collagen crosslinking in central and paracentral ectasias.

Setting:

Private practice. Novovision Murcia (Spain).

Methods:

Retrospective study recruiting patients with progressive corneal ectasia. We classified patients according to the treatment performed: conventional crosslinking (C-CXL) or transepithelial crosslinking (TE-CXL). The ectasias were categorized as “central” if the zone most thinner of cornea is displaced less than 1mm of the center of the same and as “paracentral” if it is displaced 1mm o more. A 3 years follow-up is assessed. Changes on manifest refraction (∆sph y ∆cil), best correct visual acuity (∆BCVA), keratometry (∆K), corneal astigmatism (∆CA) and corneal pachymetry (∆pachymetry) are compared between central and paracentral ectasias.

Results:

One hundred fifteen eyes were analyzed. The 38.2%of sample are central ectasias and the 60% underwent C-CXL. No corneal ectasias progression were detected after treatment. After C-CXL, paracentral ectasias presented better values of ∆K (p=0.044), ∆AC (p=0.010) and ∆pachymetry (p=0.040) than central ectasias. After TE-CXL, paracentral ectasias showed better values of ∆AC (p=0.024) than central ectasias.

Conclusions:

Corneal collagen crosslinking is most effective on paracentral ectasias. Conventional crosslinking is more effective to stop the progression of corneal ectasias.

Financial Disclosure:

NONE

Back to Poster listing